Suecia, un país de 10.171.524 hab. (2018) y con una renta per cápita (2018) de 46.310€, (aunque su moneda oficial es la corona, no el euro) miembro de la UE desde 1995, nueve años después que España, tiene una estrategia para hacer llegar los MTA a sus ciudadanos, que se apoya en varias "patas":
CAMP is a Vinnova funded project focussing on the science and technology required to translate ATMPs from lab to clinic, including bioprocess development, GMP production and logistics. CAMP drives collaboration between researchers, GMP competent resources, industry and hospitals.
Centre Director – Jukka Lausmaa
Scientific Director – Pontus Blomberg
WP1 (Work packages – Process development – Stefan Scheding
WP2 – Infrastructure for GMP manufacturing – Pontus Blomberg
WP3 – Quality control, shelf-life and logistics – Jim Lund
CCP1 (Cross cutting priorities) – Legislation, regulatory aspects and ethics – Ann Novotny
CCP2 – Swedish ATMP challenges and opportunities – Kristina Kannisto
Industry representatives;
– Mohammad Bohlooly (AstraZeneca)
– Raimund Strehl (VERIGRAFT)
Coordinator – Paul Kingham
Communications – Heather Main
Swelife-ATMP SDPs (SYSTEM DEVELOPMENT PROJECTS) address the systems and processes around ATMP development.
The following projects have commenced:
SDP1: The regulatory aspect for ATMP
SDP2: Road Map for setting the ethical and legal framework of stem cell based ATMP in Sweden SDP3: Business models and health economics for ATMPs
SDP4: Opportunities and challenges for Sweden to become internationally leading in the field of gene therapy
SDP5: Sweden’s CAR T Cell Competence Network (SWECARNET)
Vinnova es la autoridad de innovación de Suecia. Nuestra misión es fortalecer la capacidad de innovación de Suecia y contribuir al crecimiento sostenible. Trabajamos para que Suecia sea una fuerza innovadora en un mundo sostenible. (Traducido mediante translate de Google del Sueco)
Aportan recursos para financiar proyectos, ver páginas 54 y 56.
Tienen un mapa con los actores en el ámbito de los ATMP´s en Suecia en que se recogen:
35 ATMP Sweden partners
15 Facilities for manufacture or process development
68 Clinical or pre-clinical ATMPs
20 Specialist treatment clinics
Total 138
Tienen un resumen del proceso regulatorio de los ATMP´s elaborado por uno de sus grupos.
https://atmpsweden.se/atmp-regulatory-guide/
CAMP is a Vinnova funded project focussing on the science and technology required to translate ATMPs from lab to clinic, including bioprocess development, GMP production and logistics. CAMP drives collaboration between researchers, GMP competent resources, industry and hospitals.
Centre Director – Jukka Lausmaa
Scientific Director – Pontus Blomberg
WP1 (Work packages – Process development – Stefan Scheding
WP2 – Infrastructure for GMP manufacturing – Pontus Blomberg
WP3 – Quality control, shelf-life and logistics – Jim Lund
CCP1 (Cross cutting priorities) – Legislation, regulatory aspects and ethics – Ann Novotny
CCP2 – Swedish ATMP challenges and opportunities – Kristina Kannisto
Industry representatives;
– Mohammad Bohlooly (AstraZeneca)
– Raimund Strehl (VERIGRAFT)
Coordinator – Paul Kingham
Communications – Heather Main
Swelife-ATMP SDPs (SYSTEM DEVELOPMENT PROJECTS) address the systems and processes around ATMP development.
The following projects have commenced:
SDP1: The regulatory aspect for ATMP
SDP2: Road Map for setting the ethical and legal framework of stem cell based ATMP in Sweden SDP3: Business models and health economics for ATMPs
SDP4: Opportunities and challenges for Sweden to become internationally leading in the field of gene therapy
SDP5: Sweden’s CAR T Cell Competence Network (SWECARNET)
Vinnova es la autoridad de innovación de Suecia. Nuestra misión es fortalecer la capacidad de innovación de Suecia y contribuir al crecimiento sostenible. Trabajamos para que Suecia sea una fuerza innovadora en un mundo sostenible. (Traducido mediante translate de Google del Sueco)
Aportan recursos para financiar proyectos, ver páginas 54 y 56.
Tienen un mapa con los actores en el ámbito de los ATMP´s en Suecia en que se recogen:
35 ATMP Sweden partners
15 Facilities for manufacture or process development
68 Clinical or pre-clinical ATMPs
20 Specialist treatment clinics
Total 138
Tienen un resumen del proceso regulatorio de los ATMP´s elaborado por uno de sus grupos.
https://atmpsweden.se/atmp-regulatory-guide/
Comentarios
Publicar un comentario